ArticleCureus2023
Period Prevalence of COVID-19 and Influenza Symptoms in 2022 Among Adults in Jazan, Saudi Arabia.
Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeasonal influenza and the circulating new variants of coronavirus disease 2019 (COVID-19) were predicted to increase the risk of developing respiratory symptoms in 2022. The objective of this study was to estimate the period prevalence of respiratory symptoms associated with COVID-19 and influenza among adults in 2022.
methodsThis cross-sectional study targeted adults in Jazan, Saudi Arabia. Data collection was performed in February 2023 and utilized an online approach. The assessment was performed via a self-administered questionnaire, which measured demographics, vaccination practices against COVID-19 and influenza, and the occurrence of respiratory symptoms in 2022.
resultsThis study involved 625 participants, 65% of whom were women with a mean age of 23 years. Only 80 participants (13%) reported receiving the influenza vaccine in 2022. The most frequently reported symptoms were headache (55%), sore throat (43.7%), and fever (43%). Nearly 34% were diagnosed with influenza, 17% were diagnosed with COVID-19, and 8% reported coinfection of both diseases. Sixty-one percent reported the occurrence of symptoms more than once in 2022. The presence of a higher frequency of respiratory symptoms was associated with gender, age, social status, employment, asthma, and obesity (P < 0.05).
conclusionsA majority of the participants reported multiple occurrences of respiratory symptoms in 2022. The uptake of the influenza vaccine was low in the same year, suggesting a need for a targeted approach to enhance vaccination rates among vulnerable groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.